Relative cost-effectiveness of treatments for adolescent depression: 36-week results from the tads randomized trial

Domino ME, Foster EM, Vitiello B, Kratochvil CJ, Burns BJ, Silva SG, Reinecke MA, March JS

Record Status
This is an economic evaluation that meets the criteria for inclusion on NHS EED.

Bibliographic details

PubMedID
19465880

DOI
10.1097/CHI.0b013e3181a2b319

Indexing Status
Subject indexing assigned by NLM

MeSH
Adolescent; Antidepressive Agents, Second-Generation /economics /therapeutic use; Child; Cognitive Therapy /economics; Combined Modality Therapy /economics; Cost-Benefit Analysis /statistics & numerical data; Depressive Disorder, Major /economics /therapy; Double-Blind Method; Drug Costs /statistics & numerical data; Female; Fluoxetine /economics /therapeutic use; Follow-Up Studies; Hospitalization /economics; Humans; Male; Personality Assessment /statistics & numerical data; Psychometrics

AccessionNumber
22009103260

Date bibliographic record published
03/02/2010